Marshall Goldsmith

FEBRUARY 8, 2018

Darek Lenart – Senior VP HR, Finance MasterCard. Former HR director with Pepsi Central Eastern Europe, and gained HR expertise at PLIVA Pharmaceutical Company (now part of Teva Group). Sanyin Siang – Executive Director of the Duke University Fuqua/Coach K Center on Leadership & Ethics (COLE). Author: The Launch Book.

Executive Coaching 70

Executive Coaching CEO Magazine Banking 70

Harvard Business Review

JUNE 9, 2017

Equally troublesome, almost all policies focus exclusively on payments and finances but ignore the powerful influence of careerism and other non-financial motives that may compromise objectivity far more than financial incentives. For academics, publishing and obtaining grants are key to promotion and career advancement.

Conflict of Interest 10

Conflict of Interest Pharmaceuticals Policies Industry 10

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products. Experimentation is vital.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

MARCH 24, 2011

Among McKinsey's biggest clients in the 1990s were pharmaceuticals and financial-services companies. The strategy firms saw some of their best talent head off to startups, which promised untold riches, at least until the Dotbust of 2000, and to Wall Street or Greenwich or wherever the racier genii of modern finance ply their trade.

McKinsey 14

McKinsey Consultative Waterman Intellectual Capital 14

Harvard Business Review

JANUARY 10, 2013

initiative — prohibitions against off-label marketing under the False Claims Act — swept through the pharmaceutical industry. The most notable was Fannie Mae's $10.8 billion restatement. In another instance, a new enforcement. The largest payments were from Pfizer ($2.3 billion) and GlaxoSmithKline ($3 billion).

Finance 8

Finance Banking Press Release Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 19, 2016

Imagine, for example, that you’re a pharmaceutical CEO deciding whether to recall a new drug. In these cases, running the numbers and grasping what they tell you is important, but it isn’t enough. With gray area problems, you have to look hard at the economics and look past the economics. How should you make this decision?

ROI 8

ROI Long-term Conflict of Interest Pharmaceuticals 8